A better target for B-cell lymphomas: From a library of MAG antagonists to nanomolar CD22 ligands

October 25, 2011

Patients suffering from B-cell lymphomas can be treated with antibodies directed against the B-lymphocyte antigen CD20.

This therapy is not a cure, however, and new treatments that kill B-cells through different mechanisms are required, especially for patients with indolent lymphoid malignancies. An alternative clinical target for B-cell is CD22, a B-cell-specific member of the sialic acid binding Ig-like lectin (Siglec) family that recognizes α2,6-linked sialylated glycans as ligands. When it was demonstrated that B-cell activation can be down-regulated with sialosides, an intensive search for low-molecular-weight high-affinity was initiated.

A collaborative research effort led by Beat Ernst and colleagues at the University of Basel in Switzerland has identified selective and high-affinity CD22 antagonists, and their results are reported in ChemMedChem.

Using surface plasmon resonance, the team screened an existing library of antagonists (which were initially designed for another member of the Siglec family) for binding affinity toward CD22. The initial hit was then optimized to yield a series of CD22 antagonists with nanomolar binding affinity. Ernst's research group will next examine the potential application of these CD22 in cell depletion therapy.

Explore further: Targeted Tumor Therapy: When Antagonists Do the Better Job

More information: Beat Ernst, From a Library of MAG Antagonists to Nanomolar CD22 Ligands, ChemMedChem, Permalink to the article: dx.doi.org/10.1002/cmdc.201100407

Related Stories

Targeted Tumor Therapy: When Antagonists Do the Better Job

October 20, 2006

Targeted tumor therapy lobs toxic payloads directly into tumors to destroy cancer cells while leaving normal cells unharmed. In the case of radiotherapy, these missiles, which should unerringly home in on the target and make ...

Recommended for you

A marine creature's magic trick explained

September 2, 2015

Tiny ocean creatures known as sea sapphires perform a sort of magic trick as they swim: One second they appear in splendid iridescent shades of blue, purple or green, and the next they may turn invisible (at least the blue ...

New method opens pathway to new drugs and dyes

September 2, 2015

Rice University scientists have developed a practical method to synthesize chemical building blocks widely used in drug discovery research and in the manufacture drugs and dyes.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.